Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Spaarne Gasthuis | OTHER |
Not provided
Not provided
Not provided
Not provided
Rationale: Respiratory tract infections (RTI) are a major cause of morbidity in young children in high- income countries and the major cause of mortality in developing countries. Causative bacteria and viruses are regular residents of the nasopharynx of asymptomatic individuals (colonization) and live there together with other presumed harmless commensals, without causing disease. These non-pathological infections/colonization episodes are important for transmission, intermediate step to disease and boost immune responses. The investigators recently validated the use of minimally-invasive nasal sampling methods that can be done at home for the study of host and microbial parameters in adults and children. In this study the investigators will focus on the daily microbial and immunological composition of the nasopharynx during health in relation to symptoms.
Primary objective: Associate acquisition of pneumococcal colonisation with levels of pre-existing polysaccharide specific memory B cells.
Secondary objectives include: Validate the use of synthetic absorptive matrices (SAM) for detection of respiratory pathogens versus nasopharyngeal swabs (NPS) and saliva; Assess dynamics of URT infection/colonisation and examine its relationship with symptoms, host responses and microbiota; Measure transmission between children and parents and immune responses in parents.
Study design: Prospective community-based cohort study.total of 45 children, aged 1-5 years old attending daycare or (pre-)school, will be included, including a pilot of 10 children to assess tolerability. If there are insufficient pneumococcal acquisitions in the study to assess the primary outcome, additional children can be recruited in groups of 3 or 4 children (up to 10). For a subset of participating children, both parents will be asked to self-collect daily saliva during the study.
Primary study parameters: Frequency of systemic polysaccharide specific B cells in children that become colonised during the study versus children that do not become colonised Secondary study parameters: Dynamics of respiratory bacteria and viruses during URT infection/colonisation. Presence and load for bacteria and viruses in children in SAM versus saliva and NPS. Local microbiota and immune profiles and association with infection/colonisation and symptomology. For a subset of parents, daily presence and load of bacteria and viruses as well as host immune factors measured in saliva.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Young children | Children aged 1-5 years old attending school or day care. Follow-up for 28 days using minimally-invasive nasosorption sampling and questionnaires relating to symptoms. No intervention administered | ||
| Parents | Parents of enrolled children, if it is a one-child family. Follow-up for 28 days using minimally-invasive saliva sampling. No intervention administered |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of systemic polysaccharide specific B cells in children that become colonised during the study versus children that do not become colonised | up to study completion, 28 or 29 days |
| Measure | Description | Time Frame |
|---|---|---|
| The number of participants with pneumococcal colonisation presence over time. | lyta, piab and serotype-specific qPCR | up to study completion, 28 or 29 days |
| Pneumococcal colonisation density over time. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Children aged 1-6 years old, as these are a main population at risk for severe respiratory tract infections, and a main source of transmission. The study team will recruit families from the area of North/South-Holland as this will facilitate the home visits.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marlies A van Houten, MD | Spaarne Gasthuis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Spaarne Gasthuis | Hoofddorp | Netherlands |
If any samples or data are shared to perform analyses as described in the study protocol, either inside or outside EU, only pseudonymized material is shared to ensure participant privacy.
This can be done upon request and following the signing of MTA/DTA.
Individual datasets might be placed on repositories with restricted access or fully anonymized (such as Zenodo or flowrepository.org) upon publication.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007239 | Infections |
| D058345 | Asymptomatic Infections |
| ID | Term |
|---|---|
| D058070 | Asymptomatic Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Peripheral blood samples are collected at baseline (day 1) from children Nasopharyngeal swabs are collected at day 28 from children Saliva samples are collected at days 1, 14, 28 from children Nasosorption samples are collected from nose daily for entire study 28 days For a subset of parents of enrolled children, daily saliva samples are collected for 28 days
lyta, piab and serotype-specific qPCR
| up to study completion, 28 or 29 days |
| The number of participants with presence of other bacteria and viruses | Presence of other respiratory bacteria (such as Haemophilus influenzae and Staphylococcus aureus) and viruses (such as coronaviruses and influenza virus) during URT infection/colonisation, measured by molecular methods. | up to study completion, 28 or 29 days |
| Density of other bacteria and viruses | Density of other respiratory bacteria (such as Haemophilus influenzae and Staphylococcus aureus) and viruses (such as coronaviruses and influenza virus) during URT infection/colonisation, measured by molecular methods. | up to study completion, 28 or 29 days |
| Local microbiome composition measured by 16S | Relative abundance of ASV | up to study completion, 28 or 29 days |
| Nasal and systemic antibodies titres specific for identified pathogens, measured using ELISA or antigen arrays | antigen-specific IgG, IgA and IgM titres | up to study completion, 28 or 29 days |
| Nasal cytokine levels, assessed using multiplex assays such as Luminex | Individual cytokines will be reported in absolute or relative values | up to study completion, 28 or 29 days |
| Symptom questionnaires | Symptoms are scaled on presence/absence | up to study completion, 28 or 29 days |
| Evaluation/Sample tolerability questionnaires | scale includes completely disagree, disagree, neutral, agree, completely agree for each question | day 28, last visit |
| Presence of bacteria and viruses in saliva of a subset of parents on a daily interval | Measured using molecular methods | up to study completion, 28 or 29 days |
| Density of bacteria and viruses in saliva of a subset of parents on a daily interval | Measured using molecular methods | up to study completion, 28 or 29 days |